ISIS Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 13.52B 11.82B 10.86B 10.12B 19.2B 1,287B 19.49B 130B 50.69B 633B 50.74B 49.65B 2,180B | P/E 2026 * |
-22.7x | P/E 2027 * | -65x |
|---|---|---|---|---|---|
| Enterprise Value | 13.3B 11.63B 10.68B 9.96B 18.89B 1,266B 19.18B 128B 49.86B 622B 49.92B 48.85B 2,145B | EV / Sales 2026 * |
14.9x | EV / Sales 2027 * | 8.89x |
| Free-Float |
99.09% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 2012-06-30 |
Brett Monia
CEO | Chief Executive Officer | 64 | 2019-12-31 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 2000-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 2005-12-12 |
| Director/Board Member | 73 | 2002-04-30 | |
Brett Monia
BRD | Director/Board Member | 64 | 2019-03-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 13.52B | |
| +1.70% | +7.41% | +3.12% | +8.46% | 49.92B | |
| +0.92% | +3.93% | +399.71% | +605.33% | 40.23B | |
| +1.89% | +8.32% | +26.06% | -6.35% | 34.55B | |
| +2.38% | +6.35% | +21.25% | +64.58% | 33.09B | |
| +3.96% | +10.67% | +11.89% | +38.86% | 27.51B | |
| +2.51% | +5.27% | - | - | 17.05B | |
| +2.58% | +5.79% | +73.44% | +133.27% | 15.92B | |
| +0.32% | +0.58% | +13.67% | +19.09% | 13.86B | |
| -1.14% | +1.88% | +15.30% | -28.79% | 13.26B | |
| Average | +1.64% | +6.17% | +70.55% | +104.31% | 27.27B | |
| Weighted average by Cap. | +1.80% | +6.70% | +86.40% | +130.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 893M 781M 718M 669M 1.27B 85.07B 1.29B 8.62B 3.35B 41.81B 3.35B 3.28B 144B | 1.51B 1.32B 1.21B 1.13B 2.14B 143B 2.17B 14.52B 5.64B 70.44B 5.65B 5.53B 243B |
| Net income | -598M -523M -481M -448M -850M -56.98B -863M -5.77B -2.24B -28.01B -2.25B -2.2B -96.51B | -199M -174M -160M -149M -282M -18.91B -286M -1.92B -744M -9.29B -745M -729M -32.02B |
| Net Debt | -220M -192M -177M -165M -313M -20.95B -317M -2.12B -825M -10.3B -826M -808M -35.49B | -138M -121M -111M -103M -196M -13.16B -199M -1.33B -518M -6.47B -519M -507M -22.28B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
